Homepage Top Section2

According to the agreement, Moderna will use BARDA’s funding to advance its mRNA-1273 vaccine candidate to FDA licensure. The mRNA-1273 is a vaccine candidate against SARS-CoV-2 encoding for

The Chinese biopharmaceutical company said that it has been developing the COVID-19 vaccine candidate since January 2020. The firm claimed that its scientists have quickly completed comprehensive preclinical

In this regard, Hope Biosciences will be evaluating the safety and efficacy of its adipose-derived mesenchymal stem cells (HB-adMSCs) in the mid-stage clinical trial. The phase 2 trial,

The pharma company has signed an agreement with the US National Institute of Allergy and Infectious Diseases (NIAID) to investigate baricitinib as an arm in the latter’s Adaptive

The FDA approval was based on positive data from the National Cancer Institute (NCI) Cancer Therapy Evaluation Programme (CTEP)-sponsored phase II SPRINT Stratum 1 study organised by the

The latest approval from the European Commission (EC) authorises ALUNBRIG to be used as a monotherapy for the treatment of adults having anaplastic lymphoma kinase-positive (ALK+) advanced non-small

The late-stage trial met both the co-primary endpoints, with Nucala added to standard of care delivering statistically significant improvements in the size of nasal polyps at week 52

Novartis will work with Incyte to begin a phase III clinical study to assess the application of Jakavi to treat cytokine storm, a type of severe immune overreaction

Novellus’ patented process applies exclusive non-immunogenic synthetic messenger ribonucleic acid (mRNA) molecules for the creation of induced pluripotent stem cells (iPSCs). The iPSCs will be used to create